by Madaline Spencer | Jan 2, 2026
Jean-Marie Michot, MD, Institut Gustave Roussy, France, discusses results from Part 1A (dose escalation) of the OLYMPIA-3 study of odronextamab plus chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL). DLBCL is a form of non-Hodgkin...
by Madaline Spencer | Dec 30, 2025
Paolo Ghia, MD, PhD, Professor of Medical Oncology at the Università Vita-Salute San Raffaele in Milan, Italy, discusses data comparing ibrutinib plus venetoclax combination therapy with chlorambucil + obinutuzumab combination therapy in patients with chronic...
by Madaline Spencer | Dec 29, 2025
Robert Orlowski, MD, PhD, Professor of Medicine at the University of Texas MD Anderson Cancer Center, discusses results from the LINKER-MM4 clinical trial testing Lynozyfic (linvoseltamab) to treat patients with newly diagnosed multiple myeloma (MM). MM is a...
by Madaline Spencer | Dec 23, 2025
Elias Jabbour, MD, MD Anderson Cancer Center at the University of Texas, discusses the cAMeLot-2 study design of bleximenib combination therapy for patients with acute myeloid leukemia (AML). AML is a hematologic malignancy. Early signs and symptoms of...
by Madaline Spencer | Dec 22, 2025
Joseph Sullivan, MD, Professor of Neurology and Pediatrics at the University of California at San Francisco, discusses the results of the BUTTERFLY clinical trial in pediatric patients with Dravet syndrome. Dravet syndrome is the most severe of a group...
